Norkiene Ieva, Ringaitiene Donata, Rucinskas Kestutis, Samalavicius Robertas, Baublys Alis, Miniauskas Saulius, Sirvydis Vytautas
Center of Anaesthesia, Intensive Care and Pain Management, Clinic of Heart Diseases, Vilnius University Hospital, Santariskiu Clinics, Santariskiu 2, Vilnius, Lithuania.
Interact Cardiovasc Thorac Surg. 2007 Feb;6(1):66-70. doi: 10.1510/icvts.2006.140160. Epub 2006 Nov 21.
The crucial decision to progress from pharmacological treatment of acute decompensated heart failure to institution of assist device or transplantation begins with evaluation of the chances for a successful recovery. We tested whether the intra-aortic balloon counterpulsation (IABP) could give us the necessary time for clinical decision-making and preserve adequate circulation until it is made.
We assessed 11 dilated cardiomyopathy patients of NYHA class IV, listed for heart transplantation or a ventricular assist device (VAD), who had conventional IABP placed. Heart function prior to and after IABP insertion as well as hemodynamics, end-organ function (renal and hepatic), frequency of complications and clinical outcomes were assessed.
The duration of intra-aortic balloon pump insertion ranged from 72 to 360 h (mean 181.54+/-81.65). After 48 h of intra-aortic balloon pump support, there was a significant increase of mean systemic arterial pressure from 74.5+/-9.6 to 82.3+/-4.7 mmHg (P=0.02), and ejection fraction from 14.7+/-6.4 to 21.0+/-8.6 (P=0.014). Meanwhile improvement of cardiac index, pulmonary wedge pressure and end-organ perfusion markers did not reach statistical significance. Three patients were successfully weaned off the balloon and recovered without additional interventions, two patients were transplanted and three were supported with counterpulsation until the implantation of assist device. Three patients died due to progressive heart failure, two after IABP removal and one after VAD implantation. There was no incidence of infection, limb ischemia, thrombus, or embolic complications.
Our data showed that intra-aortic balloon pump support may be successfully and safely used in the acute decompensated dilated cardiomyopathy patients, as an urgent measure of cardiac support, to stabilize the patient and maintain organ perfusion until transplant is available, VAD is placed or patient is weaned from IABP.
从急性失代偿性心力衰竭的药物治疗进展到使用辅助装置或进行移植的关键决策始于对成功恢复机会的评估。我们测试了主动脉内球囊反搏(IABP)是否能为我们提供临床决策所需的时间,并在做出决策之前维持足够的循环。
我们评估了11例纽约心脏协会(NYHA)心功能IV级的扩张型心肌病患者,这些患者被列入心脏移植或心室辅助装置(VAD)名单,并接受了传统的IABP治疗。评估了IABP置入前后的心脏功能以及血流动力学、终末器官功能(肾脏和肝脏)、并发症发生率和临床结局。
主动脉内球囊泵置入的持续时间为72至360小时(平均181.54±81.65)。在主动脉内球囊泵支持48小时后,平均体动脉压从74.5±9.6显著升高至82.3±4.7 mmHg(P = 0.02),射血分数从14.7±6.4升高至21.0±8.6(P = 0.014)。同时,心脏指数、肺楔压和终末器官灌注指标的改善未达到统计学意义。3例患者成功撤掉球囊且未进行额外干预即康复,2例患者接受了移植,3例患者在植入辅助装置前接受了反搏支持。3例患者因进行性心力衰竭死亡,2例在IABP撤除后死亡,1例在VAD植入后死亡。未发生感染、肢体缺血、血栓或栓塞并发症。
我们的数据表明,主动脉内球囊泵支持可成功且安全地用于急性失代偿性扩张型心肌病患者,作为一种紧急心脏支持措施,以稳定患者病情并维持器官灌注,直至进行移植、置入VAD或患者撤掉IABP。